Tesamorelin Research Protocols: FDA-Approved Use vs Research Peptide Comparison

Tesamorelin is a synthetic GHRH (growth hormone-releasing hormone) analog that binds the GHRH receptor on pituitary somatotrophs, stimulating endogenous growth hormone release. It is the only GHRH analog FDA-approved for clinical use, indicated for HIV-associated lipodystrophy (excess visceral abdominal fat in HIV patients on antiretroviral therapy). Brand name: Egrifta. Standard FDA-approved dose: 2 mg subcutaneous daily. Versus other GHRH analogs: - **Sermorelin**: shorter half-life (~10 min in serum), lower cost, more rapid clearance. Used historically for pediatric GH deficiency (no longer FDA-approved for that since 2008) and now in research/wellness settings. - **CJC-1295 (without DAC)**: similar half-life to sermorelin (10-30 min). With DAC (drug affinity complex), half-life extends to ~8 days due to albumin binding. - **Tesamorelin**: half-life ~25-40 minutes; structurally a GHRH(1-44) analog with an N-terminal modification that resists DPP-4 degradation. Most stable of the GHRH analogs without depot extension. Clinical trials (Falutz et al, NEJM 2007 and J Clin Endocrinol Metab 2010) showed tesamorelin reduced visceral adipose tissue (VAT) by ~10-15% over 26 weeks in HIV-associated lipodystrophy patients. Outside the FDA-approved indication, research peptide users sometimes apply tesamorelin protocols for visceral fat reduction or general GH-axis support, often at lower doses than the 2 mg daily clinical dose. This content is for research and educational purposes only and does not constitute medical advice.

Tesamorelin binds GHRH receptors on anterior pituitary somatotrophs, triggering Gs-coupled signaling that elevates cAMP and stimulates GH release into circulation. The released GH then acts on liver and peripheral tissues to: - Stimulate IGF-1 production (primary mediator of most GH effects) - Promote lipolysis (fat breakdown) particularly in visceral depots - Influence protein synthesis and muscle protein turnover - Affect glucose metabolism (typically modest insulin resistance) - Affect water retention via mineralocorticoid pathways Unlike exogenous GH, tesamorelin operates within the natural feedback loop — IGF-1 and somatostatin both downregulate further GH release at high levels, providing some autoregulation. This contrasts with direct GH administration (e.g., human growth hormone, somatropin), which bypasses the GHRH-pituitary-feedback system. The N-terminal trans-3-hexenoyl group on tesamorelin protects against rapid degradation by DPP-4 (dipeptidyl peptidase-4), giving it a longer functional half-life than native GHRH while still being shorter than long-acting analogs like CJC-1295 with DAC. The result: tesamorelin produces a pulsatile GH response that mimics natural physiological release patterns more closely than continuous-release alternatives.

Egrifta SV (Theratechnologies) is the FDA-approved formulation. Standard dose: 2 mg subcutaneously once daily, typically before bedtime. Reconstitution: 2 mg vial reconstituted with the supplied 2.2 mL bacteriostatic water for injection. After reconstitution, the solution is stable for up to 14 days refrigerated. Injection sites: rotated abdominal sites (avoiding scarred or distended areas). Clinical trial data (Falutz et al 2007, 2010): - 26-week studies in HIV-associated lipodystrophy patients - VAT reduction: 10-15% on average - IGF-1 elevation: 30-100% above baseline - Side effects: injection site reactions, joint pain, peripheral edema, mild glucose intolerance - Discontinuation rates: ~5-10% in trials due to adverse events The FDA-approved indication is narrow: HIV-associated excess abdominal fat in adult patients on antiretroviral therapy. Off-label use for general visceral fat reduction or anti-aging is not FDA-supported, though some research-protocol users apply tesamorelin in these contexts. Insurance coverage for off-label use is generally not available; cost without insurance is substantial ($2,000-3,500/month at 2 mg/day clinical dose).

In research-peptide and wellness contexts (outside FDA-approved use), tesamorelin protocols vary widely. Commonly observed approaches in the research literature and protocol-tracking communities: **Lower-dose research protocols**: 1 mg/day rather than 2 mg/day. Rationale: in non-HIV-lipodystrophy users, baseline GH/IGF-1 axis is intact, so smaller GHRH stimulation may produce similar relative IGF-1 elevation with fewer adverse effects. **Cycled protocols**: 8-12 weeks on, 4-8 weeks off. Cycling rationale: GHRH receptor desensitization is a theoretical concern with continuous administration; cycling may preserve responsiveness over longer time horizons. **Combined GHRH + GHRP protocols**: tesamorelin (GHRH analog) plus a GHRP (growth hormone releasing peptide) like ipamorelin or hexarelin. The two classes act on different receptors (GHRH receptor vs ghrelin/GHS-R receptor) and produce synergistic GH release in research literature. Combined protocols typically use lower individual doses to manage side effects. **Timing**: most protocols administer at bedtime to align with natural overnight GH pulses, with the rationale that exogenous GHRH pulses near the time of natural pulses may produce additive rather than disruptive effects on circulating GH. No research protocol described here is medical advice. Anyone considering tesamorelin outside the FDA-approved indication should discuss with a qualified healthcare provider who can evaluate individual circumstances, monitor labs, and weigh risks.

Key labs to monitor: **IGF-1**: the primary biomarker for GH-axis effect. Baseline and 4-8 week follow-up. Target ranges in research protocols typically aim for the upper-quartile of age-matched normal range (NOT supraphysiological levels). IGF-1 above lab-specific normal range indicates excessive GH stimulation and increases adverse-effect risk. **Fasting glucose and HbA1c**: GH stimulation produces mild insulin resistance. Some users see fasting glucose rise 5-10 mg/dL and HbA1c rise 0.1-0.3 percentage points. Persistent or larger increases warrant dose reduction or discontinuation. **Lipid panel**: GH effects on lipids are modest but worth tracking; some research shows triglycerides decrease and HDL improves with GH-axis stimulation. **Free T3, free T4, TSH**: GH affects thyroid hormone conversion (T4 to T3); some users see free T3 increase. Monitor thyroid in users with prior thyroid issues. **Cortisol**: HPA axis interactions are minor but worth checking baseline. **CBC**: GH has mild effects on hematocrit and platelets; baseline and periodic check. Frequency: baseline labs before starting, follow-up at 4-8 weeks, then every 3-6 months on continuous protocols.

Most common adverse effects from tesamorelin clinical trials (Egrifta prescribing information): **Common (>5%)**: arthralgia (joint pain), pain in extremities, peripheral edema, myalgia. Generally mild and dose-dependent. **Less common (1-5%)**: insulin resistance, hyperglycemia, glucose intolerance. Patients with pre-existing diabetes or pre-diabetes are at higher risk. **Uncommon but notable**: carpal tunnel syndrome (related to soft tissue swelling), injection site reactions, headache, paresthesias. **Theoretical risks (long-term)**: any GH-axis stimulation has theoretical concerns about: - Cancer risk (IGF-1 is mitogenic; epidemiologic studies show modest associations between very high IGF-1 and certain cancers) - Acromegalic features at supraphysiological IGF-1 levels (jaw/hand/foot enlargement) — not seen at therapeutic doses but possible with abuse - Cardiac structural changes — long-term effects on left ventricular wall thickness with chronic GH-axis stimulation are studied in acromegaly research **Contraindications**: pregnancy (Category X — should not be used in pregnancy), active cancer, hypopituitarism with active disease. This content is for research and educational purposes only. Anyone considering tesamorelin should discuss risks with a qualified healthcare provider.

Users on tesamorelin (or any GHRH analog) protocols can log dose, timing, reconstitution dates, injection sites, lab values (IGF-1, glucose, HbA1c, lipids, CBC), and subjective symptoms over time in Dosed. The app's timeline view shows the relationship between dose changes, IGF-1 response, and side-effect onset. For users on cycled protocols (8 on / 4 off, etc.), Dosed tracks the on/off cycle and surfaces lab trend data across cycles. For users combining tesamorelin with GHRPs (ipamorelin, hexarelin), each peptide is logged separately with its own protocol parameters. This content is for research and educational purposes only and does not constitute medical advice.

| Property | Tesamorelin | Sermorelin | CJC-1295 (no DAC) | CJC-1295 (with DAC) | |---|---|---|---|---| | FDA approved | Yes (HIV lipodystrophy) | No (formerly for pediatric GH deficiency, withdrawn 2008) | No | No | | Half-life | 25-40 min | ~10 min | 10-30 min | ~8 days | | GHRH receptor agonist | Yes | Yes | Yes | Yes | | DPP-4 resistance | Yes (N-terminal modification) | No | Yes (DAC stabilization optional) | Yes (DAC stabilization) | | Typical clinical dose | 2 mg/day | 0.2-0.5 mg/day | 100-200 mcg 1-3x/day | 1-2 mg/week | | Cost (research-grade) | High | Low | Low-moderate | Moderate | | Pulsatile GH release | Yes (similar to native GHRH) | Yes | Yes | More tonic (depot) | | Side effect profile | Documented in clinical trials | Mild, less data | Mild, limited data | More water retention reports | Key clinical takeaway: tesamorelin is the only GHRH analog with robust clinical trial data and FDA approval. Sermorelin and CJC-1295 have less rigorous evidence and are used primarily in research/wellness contexts. Long-acting CJC-1295 with DAC produces more sustained GH elevation but loses the pulsatile pattern of natural GH release. This content is for research and educational purposes only and does not constitute medical advice.